1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 RESIDUE LYS 7 ORDER PARAMETER: PSI=0.82 PHI=0.69. RESIDUE LYS 27 IS OUTSIDE ALLOWED REGION IN RAMACHANDRAN MAP IN SOME STRUCTURES. RESIDUE LYS 27 ORDER PARAMETER: PSI=0.78 PHI=0.82. RESIDUE MET 29 IS OUTSIDE ALLOWED REGION IN RAMACHANDRAN MAP. RESIDUE ASN 30 IS OUTSIDE ALLOWED REGION IN RAMACHANDRAN MAP IN SOME STRUCTURES. RESIDUE ASN 30 ORDER PARAMETER: PSI=0.38 PHI=0.84. Fernandez, I. Romi, R. Szendefi, S. Martin-Eauclaire, M.-F. Rochat, H. Van Rietschtoten, J. Pons, M. Giralt, E. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking H2 N 16.023 AMINO GROUP non-polymer C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 33 14256 14263 10.1021/bi00251a038 7524673 Kaliotoxin (1-37) shows structural differences with related potassium channel blockers. 1994 US J.Biol.Chem. JBCHA3 0071 0021-9258 267 1640 Kaliotoxin, a Novel Peptidyl Inhibitor of Neuronal Bk-Type Ca(2+)-Activated K+ Channels Characterized from Androctonus Mauretanicus Mauretanicus Venom 1992 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 4033.880 KALIOTOXIN 1 man polymer no yes GVEINVKCSGSPQCLKPCKDAGMRFGKCMNRKCHCTP(NH2) GVEINVKCSGSPQCLKPCKDAGMRFGKCMNRKCHCTPX A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n Androctonus Androctonus mauretanicus mauretanicus sample 6860 Androctonus mauretanicus mauretanicus pdbx_database_status pdbx_struct_assembly pdbx_struct_oper_list struct_conf struct_conf_type repository Initial release Version format compliance Version format compliance Derived calculations Other 1 0 1995-01-26 1 1 2008-03-24 1 2 2011-07-13 1 3 2017-11-29 _pdbx_database_status.process_site Y BNL 1994-06-02 REL 11 refinement DISCOVER GLY 1 n 1 GLY 1 A VAL 2 n 2 VAL 2 A GLU 3 n 3 GLU 3 A ILE 4 n 4 ILE 4 A ASN 5 n 5 ASN 5 A VAL 6 n 6 VAL 6 A LYS 7 n 7 LYS 7 A CYS 8 n 8 CYS 8 A SER 9 n 9 SER 9 A GLY 10 n 10 GLY 10 A SER 11 n 11 SER 11 A PRO 12 n 12 PRO 12 A GLN 13 n 13 GLN 13 A CYS 14 n 14 CYS 14 A LEU 15 n 15 LEU 15 A LYS 16 n 16 LYS 16 A PRO 17 n 17 PRO 17 A CYS 18 n 18 CYS 18 A LYS 19 n 19 LYS 19 A ASP 20 n 20 ASP 20 A ALA 21 n 21 ALA 21 A GLY 22 n 22 GLY 22 A MET 23 n 23 MET 23 A ARG 24 n 24 ARG 24 A PHE 25 n 25 PHE 25 A GLY 26 n 26 GLY 26 A LYS 27 n 27 LYS 27 A CYS 28 n 28 CYS 28 A MET 29 n 29 MET 29 A ASN 30 n 30 ASN 30 A ARG 31 n 31 ARG 31 A LYS 32 n 32 LYS 32 A CYS 33 n 33 CYS 33 A HIS 34 n 34 HIS 34 A CYS 35 n 35 CYS 35 A THR 36 n 36 THR 36 A PRO 37 n 37 PRO 37 A NH2 38 n 38 NH2 38 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 A O GLY 26 A O GLY 26 A N HIS 34 A N HIS 34 3 A A HB2 H CYS CYS 14 33 1.28 4 A A HB2 H CYS CYS 14 33 1.30 5 A A HB2 H CYS CYS 14 33 1.25 8 A A HB2 H CYS CYS 14 33 1.28 9 A A HB2 H CYS CYS 14 33 1.29 3 A HIS 34 0.085 SIDE CHAIN 1 9.81 1.10 114.20 124.01 A A A CA CB SG CYS CYS CYS 14 14 14 N 1 -6.17 0.90 118.30 112.13 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 1 12.39 1.80 110.60 122.99 A A A N CA CB ASN ASN ASN 30 30 30 N 1 -17.24 2.70 111.00 93.76 A A A N CA C LYS LYS LYS 32 32 32 N 1 8.50 1.30 111.50 120.00 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 1 -19.16 2.70 111.00 91.84 A A A N CA C HIS HIS HIS 34 34 34 N 2 9.54 1.10 114.20 123.74 A A A CA CB SG CYS CYS CYS 14 14 14 N 2 -6.14 0.90 118.30 112.16 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 2 12.83 1.80 110.60 123.43 A A A N CA CB ASN ASN ASN 30 30 30 N 2 -17.54 2.70 111.00 93.46 A A A N CA C ASN ASN ASN 30 30 30 N 2 13.05 2.00 110.40 123.45 A A A CB CA C LYS LYS LYS 32 32 32 N 2 -16.92 2.70 111.00 94.08 A A A N CA C LYS LYS LYS 32 32 32 N 2 8.35 1.30 111.50 119.85 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 2 -18.84 2.70 111.00 92.16 A A A N CA C HIS HIS HIS 34 34 34 N 3 -10.53 1.40 111.70 101.17 A A A CA N CD PRO PRO PRO 12 12 12 N 3 7.87 1.10 114.20 122.07 A A A CA CB SG CYS CYS CYS 14 14 14 N 3 12.21 2.00 110.40 122.61 A A A CB CA C LYS LYS LYS 16 16 16 N 3 -6.12 0.90 118.30 112.18 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 3 13.31 1.80 110.60 123.91 A A A N CA CB ASN ASN ASN 30 30 30 N 3 -16.32 2.70 111.00 94.68 A A A N CA C ASN ASN ASN 30 30 30 N 3 8.03 1.30 111.50 119.53 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 3 -22.49 2.70 111.00 88.51 A A A N CA C HIS HIS HIS 34 34 34 N 4 8.04 1.10 114.20 122.24 A A A CA CB SG CYS CYS CYS 14 14 14 N 4 -6.16 0.90 118.30 112.14 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 4 13.18 1.80 110.60 123.78 A A A N CA CB ASN ASN ASN 30 30 30 N 4 -16.71 2.70 111.00 94.29 A A A N CA C LYS LYS LYS 32 32 32 N 4 8.40 1.30 111.50 119.90 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 4 -20.44 2.70 111.00 90.56 A A A N CA C HIS HIS HIS 34 34 34 N 4 7.95 1.20 111.50 119.45 A A A CB CA C CYS CYS CYS 35 35 35 N 5 -6.19 0.90 118.30 112.11 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 5 13.72 1.80 110.60 124.32 A A A N CA CB ASN ASN ASN 30 30 30 N 5 -16.71 2.70 111.00 94.29 A A A N CA C ASN ASN ASN 30 30 30 N 5 8.04 1.30 111.50 119.54 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 5 -21.57 2.70 111.00 89.43 A A A N CA C HIS HIS HIS 34 34 34 N 5 9.05 1.20 111.50 120.55 A A A CB CA C CYS CYS CYS 35 35 35 N 6 9.73 1.10 114.20 123.93 A A A CA CB SG CYS CYS CYS 14 14 14 N 6 -6.13 0.90 118.30 112.17 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 6 12.76 1.80 110.60 123.36 A A A N CA CB ASN ASN ASN 30 30 30 N 6 -16.97 2.70 111.00 94.03 A A A N CA C LYS LYS LYS 32 32 32 N 6 11.24 1.80 110.60 121.84 A A A N CA CB HIS HIS HIS 34 34 34 N 6 8.16 1.30 111.50 119.66 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 6 -19.77 2.70 111.00 91.23 A A A N CA C HIS HIS HIS 34 34 34 N 7 8.78 1.10 114.20 122.98 A A A CA CB SG CYS CYS CYS 14 14 14 N 7 -6.22 0.90 118.30 112.08 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 7 14.65 1.80 110.60 125.25 A A A N CA CB ASN ASN ASN 30 30 30 N 7 -20.30 2.70 111.00 90.70 A A A N CA C HIS HIS HIS 34 34 34 N 8 -6.15 0.90 118.30 112.15 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 8 11.90 1.80 110.60 122.50 A A A N CA CB ASN ASN ASN 30 30 30 N 8 8.10 1.30 111.50 119.60 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 8 -21.08 2.70 111.00 89.92 A A A N CA C HIS HIS HIS 34 34 34 N 9 7.33 1.10 114.20 121.53 A A A CA CB SG CYS CYS CYS 14 14 14 N 9 -6.19 0.90 118.30 112.11 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 9 12.29 1.80 110.60 122.89 A A A N CA CB ASN ASN ASN 30 30 30 N 9 7.96 1.30 111.50 119.46 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 9 -20.06 2.70 111.00 90.94 A A A N CA C HIS HIS HIS 34 34 34 N 9 7.30 1.20 111.50 118.80 A A A CB CA C CYS CYS CYS 35 35 35 N 10 10.50 1.10 114.20 124.70 A A A CA CB SG CYS CYS CYS 14 14 14 N 10 -6.17 0.90 118.30 112.13 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 10 12.62 1.80 110.60 123.22 A A A N CA CB ASN ASN ASN 30 30 30 N 10 -16.65 2.70 111.00 94.35 A A A N CA C ASN ASN ASN 30 30 30 N 10 12.97 2.00 110.40 123.37 A A A CB CA C LYS LYS LYS 32 32 32 N 10 -16.85 2.70 111.00 94.15 A A A N CA C LYS LYS LYS 32 32 32 N 10 8.28 1.30 111.50 119.78 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 10 -19.03 2.70 111.00 91.97 A A A N CA C HIS HIS HIS 34 34 34 N 11 -6.13 0.90 118.30 112.17 A A A CB CG OD2 ASP ASP ASP 20 20 20 N 11 16.86 2.70 111.00 127.86 A A A N CA C CYS CYS CYS 33 33 33 N 11 7.86 1.30 111.50 119.36 A A A ND1 CE1 NE2 HIS HIS HIS 34 34 34 N 11 -19.76 2.70 111.00 91.24 A A A N CA C HIS HIS HIS 34 34 34 N 1 A A CD OE2 GLU GLU 3 3 0.119 0.011 1.252 1.371 N 2 A A CD OE2 GLU GLU 3 3 0.119 0.011 1.252 1.371 N 3 A A CD OE2 GLU GLU 3 3 0.118 0.011 1.252 1.370 N 3 A A CG CD2 HIS HIS 34 34 0.054 0.009 1.354 1.408 N 4 A A CD OE2 GLU GLU 3 3 0.119 0.011 1.252 1.371 N 5 A A CD OE2 GLU GLU 3 3 0.118 0.011 1.252 1.370 N 6 A A CD OE2 GLU GLU 3 3 0.120 0.011 1.252 1.372 N 7 A A CD OE2 GLU GLU 3 3 0.118 0.011 1.252 1.370 N 8 A A CD OE2 GLU GLU 3 3 0.119 0.011 1.252 1.371 N 9 A A CD OE2 GLU GLU 3 3 0.119 0.011 1.252 1.371 N 10 A A CD OE2 GLU GLU 3 3 0.119 0.011 1.252 1.371 N 11 A A CD OE2 GLU GLU 3 3 0.119 0.011 1.252 1.371 N 1 A LYS 7 166.46 79.73 1 A CYS 8 -161.61 92.20 1 A SER 9 -100.58 67.73 1 A SER 11 -40.21 -88.90 1 A PRO 12 -64.95 88.34 1 A GLN 13 168.12 -49.66 1 A CYS 14 -100.33 -60.19 1 A CYS 18 -100.38 50.95 1 A ALA 21 -121.75 -91.31 1 A PHE 25 -178.90 -35.27 1 A LYS 27 45.10 157.20 1 A MET 29 85.30 124.79 1 A ASN 30 96.69 -67.01 1 A CYS 33 -32.41 155.75 2 A LYS 7 71.29 106.89 2 A CYS 8 -151.17 83.85 2 A SER 9 -100.28 70.86 2 A SER 11 -40.71 -93.38 2 A PRO 12 -60.94 90.48 2 A GLN 13 165.84 -51.14 2 A CYS 18 -101.07 50.72 2 A ASP 20 -139.39 -35.71 2 A ALA 21 -109.31 -87.52 2 A MET 23 -150.58 -70.85 2 A PHE 25 -173.73 -37.86 2 A LYS 27 51.90 159.29 2 A MET 29 77.78 125.87 2 A ASN 30 103.65 -72.26 2 A CYS 33 -33.68 154.67 3 A LYS 7 62.44 113.43 3 A CYS 8 -152.87 89.45 3 A SER 9 -100.57 61.70 3 A SER 11 -52.13 -93.18 3 A PRO 12 -61.87 89.11 3 A GLN 13 174.86 -59.53 3 A ALA 21 -137.01 -87.41 3 A MET 23 -145.60 -71.14 3 A PHE 25 161.75 -20.70 3 A LYS 27 65.11 160.80 3 A MET 29 87.57 134.43 3 A ASN 30 99.85 -72.23 3 A CYS 33 -37.09 150.84 4 A LYS 7 162.38 88.39 4 A CYS 8 -163.19 97.46 4 A SER 11 -53.57 -85.64 4 A PRO 12 -63.40 88.16 4 A GLN 13 173.89 -60.04 4 A CYS 18 -100.16 44.85 4 A ALA 21 -112.03 -95.71 4 A MET 23 -150.26 -64.60 4 A PHE 25 -176.57 -34.41 4 A LYS 27 60.15 152.69 4 A MET 29 94.09 130.27 4 A ASN 30 98.20 -68.85 4 A CYS 33 -32.64 154.45 5 A VAL 2 -119.12 57.11 5 A LYS 7 65.15 120.28 5 A CYS 8 -160.53 111.98 5 A SER 9 -92.78 58.23 5 A SER 11 -56.02 -86.90 5 A PRO 12 -62.43 88.44 5 A GLN 13 174.08 -65.24 5 A ALA 21 -109.81 -93.22 5 A MET 23 -142.06 -71.81 5 A PHE 25 172.02 -19.75 5 A LYS 27 62.45 142.12 5 A MET 29 83.82 136.67 5 A ASN 30 103.34 -70.86 5 A CYS 33 -33.88 152.70 6 A LYS 7 68.96 112.71 6 A SER 9 -100.52 58.40 6 A SER 11 -44.80 -87.93 6 A PRO 12 -65.70 87.28 6 A GLN 13 171.24 -50.11 6 A CYS 14 -100.53 -60.48 6 A CYS 18 -100.62 50.67 6 A ASP 20 -139.71 -30.70 6 A ALA 21 -117.87 -85.31 6 A MET 23 -142.09 -70.75 6 A PHE 25 166.57 -60.65 6 A LYS 27 -49.55 167.47 6 A MET 29 83.60 128.95 6 A ASN 30 101.70 -70.03 6 A CYS 33 -34.46 154.64 7 A VAL 2 -112.29 63.17 7 A LYS 7 57.16 98.73 7 A SER 11 -57.27 -91.53 7 A PRO 12 -58.25 90.50 7 A GLN 13 171.18 -67.82 7 A LYS 16 -59.54 -74.58 7 A ASP 20 -147.28 -32.55 7 A ALA 21 -95.32 -93.31 7 A MET 23 -147.61 -69.63 7 A PHE 25 -172.73 -44.02 7 A LYS 27 58.98 145.09 7 A MET 29 62.34 125.84 7 A ASN 30 103.04 -61.65 7 A CYS 33 -35.93 154.06 8 A ILE 4 -106.22 41.70 8 A LYS 7 57.30 110.71 8 A SER 11 -54.38 -84.62 8 A PRO 12 -63.96 88.53 8 A GLN 13 174.75 -62.16 8 A CYS 18 -100.20 43.58 8 A ASP 20 -140.92 -23.19 8 A ALA 21 -108.26 -95.44 8 A MET 23 -147.76 -66.95 8 A PHE 25 -178.69 -33.68 8 A LYS 27 72.86 151.04 8 A MET 29 95.32 134.26 8 A ASN 30 96.77 -68.92 8 A CYS 33 -35.89 153.00 9 A VAL 2 -112.54 74.55 9 A LYS 7 177.49 102.92 9 A CYS 8 -169.97 107.44 9 A SER 9 -98.26 59.04 9 A SER 11 -54.86 -89.53 9 A PRO 12 -61.61 89.39 9 A GLN 13 174.23 -63.45 9 A CYS 18 -100.11 47.38 9 A ASP 20 -141.52 -19.82 9 A ALA 21 -111.25 -95.77 9 A MET 23 -144.57 -72.86 9 A PHE 25 174.76 -43.06 9 A LYS 27 -29.73 158.40 9 A MET 29 94.75 129.33 9 A ASN 30 98.18 -69.45 9 A CYS 33 -37.18 149.34 10 A ILE 4 -105.88 43.60 10 A LYS 7 70.15 125.98 10 A SER 9 -98.26 56.82 10 A SER 11 -47.66 -84.80 10 A PRO 12 -64.34 88.02 10 A GLN 13 168.98 -51.28 10 A CYS 18 -100.02 47.97 10 A ALA 21 -114.01 -87.14 10 A MET 23 -138.20 -74.03 10 A PHE 25 174.53 -21.34 10 A LYS 27 57.38 141.56 10 A MET 29 85.71 127.50 10 A ASN 30 102.68 -72.71 10 A CYS 33 -34.22 156.33 11 A LYS 7 58.04 109.09 11 A SER 11 -55.03 -77.25 11 A PRO 12 -64.54 86.78 11 A GLN 13 168.93 -59.21 11 A CYS 14 -97.32 -60.41 11 A CYS 18 -100.31 41.28 11 A ALA 21 -133.68 -100.97 11 A MET 23 -143.16 -64.37 11 A PHE 25 -171.60 -39.38 11 A LYS 27 54.25 158.79 11 A MET 29 83.02 -59.44 11 A CYS 33 -33.60 146.69 11 A HIS 34 -103.18 78.82 KALIOTOXIN (KTX) (NMR, 11 STRUCTURES) KALIOTOXIN (1-37) SHOWS STRUCTURAL DIFFERENCES WITH RELATED POTASSIUM CHANNEL BLOCKERS 1 Y N A PRO 12 A PRO 12 HELX_P BENT HELIX A PRO 17 A PRO 17 1 A 6 A CYS 18 A CYS 18 HELX_P A ASP 20 A ASP 20 5 A1 3 disulf 2.009 A CYS 8 A SG CYS 8 1_555 A CYS 28 A SG CYS 28 1_555 disulf 1.996 A CYS 14 A SG CYS 14 1_555 A CYS 33 A SG CYS 33 1_555 disulf 2.014 A CYS 18 A SG CYS 18 1_555 A CYS 35 A SG CYS 35 1_555 covale 1.323 A PRO 37 A C PRO 37 1_555 A NH2 38 A N NH2 38 1_555 NEUROTOXIN(POTASSIUM CHANNEL INHIBITOR) NEUROTOXIN(POTASSIUM CHANNEL INHIBITOR) SCK1_ANDMA UNP 1 1 P24662 1 37 1KTX 1 37 P24662 A 1 1 37 2 anti-parallel A PHE 25 A PHE 25 A GLY 26 A GLY 26 A HIS 34 A HIS 34 A CYS 35 A CYS 35 BINDING SITE FOR RESIDUE NH2 A 38 Software 1 A PRO 37 A PRO 37 1 1_555 1 P 1